What are the drug indications of Vonoprazan Fumarate ?

Vonoprazan Fumarate is a potassium-competitive acid blocker that is the first of its kind. It received market approval in Japan in February 2015.

P-CABs, such as vonoprazan, are a novel and heterogeneous class of medicines that completely block the potassium binding site of gastric H+/K+ ATPase, potentially circumventing the limits of protonpump inhibitors.

Vonoprazan fumarate is used to treat gastroduodenal ulcers (including some drug-induced peptic ulcers) and reflux esophagitis, and it can be used in conjunction with antibiotics to eradicate Helicobacter pylori.

Vonoprazan-amoxicillin co-packaged combinations and vonoprazan-amoxicillin and clarithromycin co-packaged combinations were approved for medicinal use in the United States in May 2022.

Newsletter Updates

Enter your email address below to subscribe to our newsletter

One comment

  1. There are a few drug indications for Vonoprazan Fumarate. It is generally used to treat advanced stage cancer, but there are a few limited indications for it. It is also being used to treat a rare form of leukemia.

    It is not recommended for pregnant women or people who are breastfeeding.

    Alternative Names: Takeda (Originator); TAK-438; TAKECAB; Vocinti; VONOPION®; Vonoprazan fumarate; VONOSAP®; VOQUEZNA DUAL PAK; VOQUEZNA TRIPLE PAK

    Check out more:


Leave a Reply

Your email address will not be published. Required fields are marked *